Trial · NCT06122285
Registered outcomes24
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 24
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Describe the virological response to BLV in all patients starting BLV therapy for CHD | Month 6 | Percentage of patients with undetectable HDV RNA |
| Primary | Describe the virological response to BLV in all patients starting BLV therapy for CHD | Month 12 | Percentage of patients with ≥ 2 log IU/ml decline of HDV RNA |
| Secondary | Evaluation of the proportion of patients with virological response, defined as a >2 Log decline in HDV-RNA | Month 6 | Proportion of patients with virological response, defined as a \>2 Log decline in HDV-RNA |
| Secondary | Evaluation of the proportion of patients with virological response, defined as a >2 Log decline in HDV-RNA | Month 12 | Proportion of patients with virological response, defined as a \>2 Log decline in HDV-RNA |
| Secondary | Evaluation of the proportion of patients with virological response, defined as undetectable HDV-RNA | Month 6 | Proportion of patients with virological response, defined as undetectable HDV-RNA |
| Secondary | Evaluation of the proportion of patients with virological response, defined as undetectable HDV-RNA | Month 12 | Proportion of patients with virological response, defined as undetectable HDV-RNA |
| Secondary | Evaluation of the percentage of patients with >2 Log decrease in HDV-RNA along with normalization of ALT | Month 6 | Percentage of patients with \>2 Log decrease in HDV-RNA along with normalization of ALT |
| Secondary | Evaluation of the percentage of patients with >2 Log decrease in HDV-RNA along with normalization of ALT | Month 12 | Percentage of patients with \>2 Log decrease in HDV-RNA along with normalization of ALT |
| Secondary | Evaluation of the percentage of patients with normal ALT | Month 6 | Percentage of patients with normal ALT |
| Secondary | Evaluation of the percentage of patients with normal ALT | Month 12 | Percentage of patients with normal ALT |
| Secondary | Evaluation of the percentage of patients with clinical response, i.e., the percentage of patients who remain free of liver complications, such as HCC or decompensation | Month 6 | Percentage of patients who remain free of liver complications (de novo HCC or onset of decompensation) |
| Secondary | Evaluation of the percentage of patients with clinical response, i.e., the percentage of patients who remain free of liver complications, such as HCC or decompensation | Month 12 | Percentage of patients who remain free of liver complications (de novo HCC or onset of decompensation) |
| Secondary | Investigation of changes over time in serum levels of HBsAg (UI/mL) | Month 6 | Change in serum levels of HBsAg- by medians and ranges |
| Secondary | Investigation of changes over time in serum levels of HBsAg (UI/mL) | Month 12 | Change in serum levels of HBsAg- by medians and ranges |
| Secondary | Investigation of changes over time in serum levels of albumin (g/dL) | Month 6 | Change in serum levels albumin- by medians and ranges |
| Secondary | Investigation of changes over time in serum levels of albumin (g/dL) | Month 12 | Change in serum levels albumin- by medians and ranges |
| Secondary | Investigation of changes over time in serum levels of platelets (10e9/L) | Month 6 | Change in serum levels of platelets - by medians and ranges |
| Secondary | Investigation of changes over time in serum levels of platelets (10e9/L) | Month 12 | Change in serum levels of platelets - by medians and ranges |
| Secondary | Investigation of changes over time in serum levels of AFP (µg/L) | Month 6 | Change in serum levels of AFP - by medians and ranges |
| Secondary | Investigation of changes over time in serum levels of AFP (µg/L) | Month 12 | Change in serum levels of AFP - by medians and ranges |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT06122285/registered